Valneva’s Restructuring Gamble: Lyme Vaccine Hopes Could Offset Steep Losses and Layoffs

Valneva cuts over 10% of staff and reduces costs by 35% amid a widening net loss, while its Lyme vaccine VLA15 shows >70% efficacy and awaits FDA/EU filing later this year.

Valneva is slashing costs and cutting more than a tenth of its workforce to weather a punishing period, even as its most advanced pipeline asset — a Lyme disease vaccine developed with Pfizer — closes in on regulatory submission. The French biotech’s stock has lost 41% of its value since the start of the year, weighed down by the fallout from its Chikungunya vaccine withdrawal and a widening net loss.

The company reported a first-quarter net loss of €32.1 million for 2026, compared with a loss of €9.2 million a year earlier, as lower product sales took their toll. In response, management plans to reduce operating costs by up to 35% this year and exit the distribution of third-party products, a business that had already slumped sharply in the opening months. Revenue for the full year is now forecast at a maximum of €160 million, with product sales contributing as much as €150 million.

That pain is etched into the share price. The stock closed at €2.26 on Thursday, just 6% above its 52-week low hit in early May and a staggering 56% below the August 2025 peak of €5.16. The 200-day moving average stands at €3.56, meaning the shares trade 36% below that mark, while 30-day volatility of over 38% underscores the deep uncertainty baked into the valuation.

On the other side of the ledger sits the Lyme vaccine candidate VLA15, also referred to as LB6V in some disclosures. Final Phase 3 data released in March 2026 showed efficacy above 70% in people aged five and older, with no safety issues flagged. Pfizer, Valneva’s partner on the programme, is preparing to file for approval in both the United States and the European Union later this year. Shareholders voiced their backing at the annual general meeting on June 25. A successful launch would unlock milestone payments and royalties for Valneva, putting sustainable profitability — targeted for 2027 — within reach.

But the memory of IXCHIQ hangs over any regulatory optimism. In August 2025, the U.S. Food and Drug Administration suspended that Chikungunya vaccine’s approval process after reports of severe side effects, including one death linked directly to the shot. Valneva voluntarily withdrew the U.S. application in January 2026, effectively killing the drug’s prospects in the world’s largest vaccine market. The episode serves as a stark reminder that strong clinical data do not guarantee a smooth path to market.

Compounding the pressure, the company’s travel-vaccine franchise is suffering from geopolitical tensions that have sapped demand. The restructuring — which also includes shedding more than 10% of global staff and tightening capital allocation — is designed to conserve cash for essential research. The operating cash burn is expected to decline notably this year.

Valneva is not putting all its eggs in one basket. A Shigella vaccine candidate is advancing through early-stage trials, with Phase 2 data due this summer. A decision on next steps will come in the second half of 2026. If that programme also shows promise, it could provide a second pillar alongside the Lyme collaboration.

Near-term, all eyes are on Pfizer’s formal submissions for VLA15 in the coming months. Any delay or regulatory hiccup reminiscent of the IXCHIQ saga would almost certainly keep the stock under pressure. The relative strength index at 40.6 suggests the shares are neither oversold nor poised for a rebound. Valneva is making itself leaner and betting heavily on a blockbuster — a high-stakes reshuffle that will leave investors watching the mailroom for the next filing from Pfizer.